2.50
Hdl Handle:
http://hdl.handle.net/2436/15858
Title:
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Authors:
Jones, Sarah; Howl, John D.
Abstract:
The past decade has witnessed a rapid expansion of our understanding of the biological roles of cannabinoids and their cognate receptors. It is now certain that Delta9-tetrahydrocannabinol, the principle psychoactive component of the Cannabis sativa plant, binds and activates membrane receptors of the 7-transmembrane domain, G-protein-coupled superfamily. Several putative endocannabinoids have since been identified, including anandamide, 2-arachidonyl glycerol and noladin ether. Synthesis of numerous cannabinomimetics has also greatly expanded the repertoire of cannabinoid receptor ligands with the pharmacodynamic properties of agonists, antagonists and inverse agonists. Collectively, these ligands have proven to be powerful tools both for the molecular characterisation of cannabinoid receptors and the delineation of their intrinsic signalling pathways. Much of our understanding of the signalling mechanisms activated by cannabinoids is derived from studies of receptors expressed by tumour cells; hence, this review provides a succinct summary of the molecular pharmacology of cannabinoid receptors and their roles in tumour cell biology. Moreover, there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases. Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents.
Citation:
Expert Opinion on Therapeutic Targets, 7(6): 749-758
Publisher:
Taylor & Francis (Informa Healthcare)
Issue Date:
2003
URI:
http://hdl.handle.net/2436/15858
DOI:
10.1517/14728222.7.6.749
PubMed ID:
14640910
Additional Links:
http://www.expertopin.com/doi/abs/10.1517/14728222.7.6.749; http://dx.doi.org/10.1517/14728222.7.6.749
Type:
Article
Language:
en
Description:
Metadata only
ISSN:
1744-7631
Appears in Collections:
Molecular Pharmacology Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorJones, Sarah-
dc.contributor.authorHowl, John D.-
dc.date.accessioned2008-01-09T10:31:06Z-
dc.date.available2008-01-09T10:31:06Z-
dc.date.issued2003-
dc.identifier.citationExpert Opinion on Therapeutic Targets, 7(6): 749-758en
dc.identifier.issn1744-7631-
dc.identifier.pmid14640910-
dc.identifier.doi10.1517/14728222.7.6.749-
dc.identifier.urihttp://hdl.handle.net/2436/15858-
dc.descriptionMetadata onlyen
dc.description.abstractThe past decade has witnessed a rapid expansion of our understanding of the biological roles of cannabinoids and their cognate receptors. It is now certain that Delta9-tetrahydrocannabinol, the principle psychoactive component of the Cannabis sativa plant, binds and activates membrane receptors of the 7-transmembrane domain, G-protein-coupled superfamily. Several putative endocannabinoids have since been identified, including anandamide, 2-arachidonyl glycerol and noladin ether. Synthesis of numerous cannabinomimetics has also greatly expanded the repertoire of cannabinoid receptor ligands with the pharmacodynamic properties of agonists, antagonists and inverse agonists. Collectively, these ligands have proven to be powerful tools both for the molecular characterisation of cannabinoid receptors and the delineation of their intrinsic signalling pathways. Much of our understanding of the signalling mechanisms activated by cannabinoids is derived from studies of receptors expressed by tumour cells; hence, this review provides a succinct summary of the molecular pharmacology of cannabinoid receptors and their roles in tumour cell biology. Moreover, there is now a genuine expectation that the manipulation of cannabinoid receptor systems may have therapeutic potential for a diverse range of human diseases. Thus, this review also summarises the demonstrated antitumour actions of cannabinoids and indicates possible avenues for the future development of cannabinoids as antitumour agents.en
dc.language.isoenen
dc.publisherTaylor & Francis (Informa Healthcare)en
dc.relation.urlhttp://www.expertopin.com/doi/abs/10.1517/14728222.7.6.749en
dc.relation.urlhttp://dx.doi.org/10.1517/14728222.7.6.749en
dc.subjectCannabinoid receptor systemsen
dc.subjectTumoursen
dc.subjectInterventionen
dc.subjectSignal Transductionen
dc.subjectEndocannabinoiden
dc.titleCannabinoid receptor systems: therapeutic targets for tumour intervention.en
dc.typeArticleen

Related articles on PubMed

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.